Bharat Biotech International Ltd on Tuesday said it will ramp up production of its COVID-19 vaccine Covaxin to about 70 crore doses on an annual basis, news agency Bloomberg reported.
The expansion in production comes after Centre last week provided them ₹65 crore grant.“Inactivated vaccines, while highly safe, are extremely complex and expensive to manufacture, resulting in lower yields when compared to live virus vaccines," the Hyderabad-based company said in a statement on Tuesday."The company is able to expand COVAXIN manufacturing capacity in a short timeline, mainly due to the availability of new specially designed BSL- 3 facilities, first of its kind for manufacturing in India that have been repurposed and preexisting expertise and.